Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
Business Wire•17/11/2026•08:00 ET
0
Key Highlights
- ➤Kernal Bio receives IFLI investment to accelerate KR-402 development in follicular lymphoma
- ➤KR-402 development complemented by up to $48 million in ARPA-H funding
- ➤Kernal Bio appoints Kirsten Kester as Chief Business Officer
- ➤Kernal Bio appoints Sieun K. Barnes as Director of Process Development
- ➤Stuart Chaffee joins Kernal Bio’s Board; Carol O’Hear and Patrick Lundgren become observers
Expert Statements
Yusuf Erkul, Co-Founder and CEO of Kernal Bio
“We’re honored to partner with IFLI to advance KR‑402 toward the clinic”
Manfred Kraus, Senior Vice President of R&D Therapeutics at Kernal Bio
“With support from IFLI, ARPA-H, and our ecosystem of partners, we are accelerating the transformation of CAR‑T therapy to an in vivo approach that could improve the patient journey and expand patient access for serious diseases”
David McCullagh, Managing Director of IFLI
“IFLI is proud to support the development of KR-402 as part of our commitment to catalyzing next-generation treatments for follicular lymphoma”
David McCullagh, Managing Director of IFLI
“Based on compelling preclinical data, Kernal Bio's in vivo CAR-T platform has the potential to address important limitations of current approaches, including lengthy manufacturing timelines and treatment complexity, and ultimately broaden access to transformative immunotherapies for the follicular lymphoma”
Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
* The Institute for Follicular Lymphoma Innovation (IFLI) provides funding to support development of KR‑402 in Follicular Lymphoma
Get started
Create a free account to read the full story.
